This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human CXADR / CAR Protein, His Tag
catalog :
CXR-H5222
quantity :
100 ug, 1 mg
price :
250 USD, 1440 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
CXR-H5222
product name :
Human CXADR / CAR Protein, His Tag
quantity :
100 ug, 1 mg
price :
250 USD, 1440 USD
quantity & price :
$250/100ug,$1440/1mg
target :
CXADR
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human CXADR, His Tag (CXR-H5222) is expressed from human 293 cells (HEK293). It contains AA Leu 20 - Gly 237 (Accession # NP_001329.1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human CXADR, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Coxsackie virus and adenovirus receptor (CXADR) is also known as CAR, is a type I transmembrane glycoprotein for group B coxsackie viruses and subgroup C adenoviruses, and belongs to the CTX family of the Ig superfamily. CAR is strongly expressed in the developing central nervous system. It functions as a homophilic and also as a heterophilic cell adhesion molecule through its interactions with extracellular matrix glycoproteins such as: fibronectin, agrin, laminin-1 and tenascin-R. Human CXADR protein contains a signal sequence, a extracellular domain (ECD) with a V type (D1) and a C2 type (D2) Iglike domain, a transmembrane segment and a intracellular domain. D1 is thought to be responsible for homodimer formation in trans within tight junctions, and is necessary and sufficient for adenovirus binding. Variants of CXADR are attached to the cell membrane by a GPI- anchor.
References :
(1) Bergelson JM, et al., 1997, Science 275 (5304): 1320–3.
(2) Tomko RP, et al., 1997, Proc Natl Acad Sci U S A 94 (7): 3352–6.
(3) Patzke C, et al., 2010, Journal of Neuroscience 30 (8): 2897–2910.
(4) Raschperger, E. et al., 2006, Exp. Cell Res. 312: 1566-80.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments